Search ARM

Invectys, transforming innovative immunotherapies to eradicate cancer, is a clinical stage immuno-oncology company spun-out of the world-renowned Pasteur Institute in, Paris. Invectys has two wholly owned subsidiaries, Invectys, S.A. (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston), whose lead product is the development of a first-in-human HLAG /CAR T initiative. Since 2010, Invectys has raised over $63 million in private funds to develop two innovative platforms of immunotherapy products which that target “universal” tumor antigens. Invectys has also received a grant of $14.2 million from the Cancer Prevention and Research Institute of Texas (Grant ID DP200034) to help fund it’s HLA-G CAR T program.

Contact Invectys, Inc
Visit Website